Pay in 4 interest-free payments of $6.39 Learn more
Ships within 48 hours · Estimated delivery Nov 7 - Nov 12
PMC 8719286
J Nanosci Nanotechnol 21(10):53525362 Vital M et al (2013) A gene-targeted approach to investigate the intestinal butyrate-producing bacterial community
This demonstrates how pairing targeted medication access with behavior change drives both outcomes and cost avoidance
[4] [2] Clinical trials have demonstrated substantial reductions in hemoglobin A1c (up to 2.5%) and body weight (approximately 15-22.5% depending on dose in the SURMOUNT-1 trial), making it a significant advancement in metabolic disease treatment
Lipids 42 , 10851092 (2007)
US$ 23.34
US$ 25.18
US$ 26.98
US$ 29.86
US$ 27.55
US$ 29.21
US$ 29.63
